Global Anti-Diabetic Drug Market Size, Share, Opportunities, And Trends By Diabetes Type (Type 1, Type 2), By Drug Type (Amylinomimetic drug, Biguanides, Alpha-glucosidase inhibitors, Sodium-glucose transporter (SGLT) 2 inhibitors, Others), By Route of Administration (Oral, Insulin), By Sales Channel (Presciption, Over-The-Counter (OTC)), And By Geography - Forecasts From 2025 To 2030

Anti-Diabetic Drug Market Size

The global anti-diabetic drug market is projected to grow at a CAGR of 9.33%, from US$153.176 billion in 2025 to US$229.19 billion in 2030.

Drugs for diabetes are called anti-diabetic drugs that increase the blood sugar level. They act by increasing the production of human insulin, making the human body's response better to the insulin, or even by reducing the absorption of sugar from their food. As a type of antidiabetic drug, they also include insulin, which requires insulin injection due to its inadequacy in the pancreas for the case of type 1 diabetes and some patients with type 2. Oral hypoglycemic agents, namely sulfonylureas, biguanides, thiazolidinediones, DPP-4 inhibitors, and alpha-glucosidase inhibitors, are some of the drugs used. SGLT2 inhibitors can be another alternative for lowering blood sugar.

The choice of antidiabetic drug depends upon the classification of diabetes, the case history of the individual, and other attributes of the patients. The global market for antidiabetic drugs has developed due to a rising hold on type 2 diabetes, the huge increase in the geriatric population, technological developments, awareness, and early intervention, including the launch of novel therapies like GLP-1 receptor agonists and SGLT2 inhibitors, as well as government initiatives enabling enhanced access to diabetes care and medications. Obesity, sedentary lifestyle, and the aging population are the major attributes for the escalation in diabetes, largely of the type 2 variant. This development is predicted to happen because of more advanced and better antidiabetic drugs that are lower in side effects, even more improved in their efficiency, and much safer. Government initiatives contribute to driving market growth.

Anti-Diabetic Drug Market Growth Drivers:

• The rising prevalence of diabetes is expected to accelerate the expansion of the global anti-diabetic drug market.

The rising prevalence of diabetes worldwide is the primary driver of the global anti-diabetic drug market. According to the International Diabetes Foundation, in 2019, approximately 463 million adults (20-79 years) had diabetes which is projected to rise to 700 million by 2045. The significant market growth is attributed to the increasing number of patients suffering from Type 2 diabetes in different regions. According to the International Diabetes Foundation, the number of people with Type 2 diabetes is increasing in many countries.

• The unhealthy dietary habits to augment profitability are anticipated to fuel the growth of the global anti-diabetic drug market.

The unhealthy habits people follow in food consumption of all ages cause a huge increase in diabetic patients all over the world. Additionally, the rise in treating the disease cost is promoting the withdrawal from the very small market. Therefore, there is a steady growth in the global market of anti-diabetic drugs. Unhealthy dietary habits affect the subject of the anti-diabetic drugs that the global market is tending towards, along with the increased risk for type 2 diabetes, neglecting disease management, and the obesity epidemic.

High-fat, processed foods, and sugary drinks contribute to the development of type 2 diabetes, increasing demand for anti-diabetic medications. Even those already diagnosed with diabetes may experience worsening blood sugar control, necessitating higher doses or additional medications. Therefore, unhealthy diets are a major contributor to the global obesity epidemic. Rising government expenditure and health awareness campaigns to treat diabetes effectively boost global anti-diabetic drug market growth.

• The sale of OTC anti-diabetic drugs is on the rise.

The prescribed anti-diabetic drug market holds a noteworthy market share throughout the forecast period. This is because these drugs are prescribed to patients by doctors with other diabetes-related therapies. Moreover, the wrong dosage of some drugs can lead to a harmful impact on the patient’s health.

However, many pharmaceutical companies are launching OTC anti-diabetic drugs, especially in emerging economies, as these are cheaper than the prescribed drugs. Thus, the OTC ant-diabetic drug market will experience significant growth owing to rising sales in developing economies.

Anti-Diabetic Drug Market Geographical Outlook:

• North America region to hold considerable shares of the global anti-diabetic drug market.

Geographically, the global anticoagulants market has been segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. By geography, North America holds a significant market share. Regionally, the global anti-diabetic drug market is classified into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. North America accounted for a significant share of the global anti-diabetic drug market in the coming years.

The presence of major pharmaceutical companies in the region contributes significantly to the notable market share of this region in the global anti-diabetic drug market. The increasing number of diabetic patients in countries like the U.S. and Canada is augmenting the demand for anti-diabetic drugs.

According to the Centers for Disease Control and Prevention (CDC), more than 100 million American adults suffer from diabetes or prediabetes. As per the statistics provided by the Canada Diabetes Association, around 90 percent of diabetic Canadians have Type 2 diabetes. Furthermore, there has been a rise in the prevalence of diabetes among children due to an unhealthy lifestyle. In the U.S., for example, the rate of newly diagnosed cases of Type 1 diabetes among kids aged 0-19 rose by 4.2 percent annually.

APAC region is projected to witness substantial market growth during the forecast period owing to the continuous rise in diabetic patients in countries like China, India, and South Korea. The easy availability of cheaper OTC (over-the-counter) anti-diabetic drugs in Asia Pacific countries is also contributing to the market growth of the region’s anti-diabetic drug market in years to come.

Anti-Diabetic Drug Market Key Developments:

• April 2024- Sanofi India Limited released an Indian version of Sanofi's diabetes drug Soliqua® which was seen as the easiest possible once-a-day delivery for adults suffering from obesity and type 2 diabetes. The medicine has obtained regulatory approvals from the Central Drugs Standard Control Organisation (CDSCO) and is to improve glycemic control and be used as an adjunct to diet and exercise in those insufficiently satisfied with oral or injectable therapy.
• January 2024- Glenmark Pharmaceuticals Ltd. produced a biosimilar of Liraglutide-a frequently used antidiabetic drug. The product is called Lirafit™ and will be distributed under the name Lirafit™, approved by the Indian DCGI. The cost of this drug is about INR 100 for the standard dosage of 1.2 mg daily. It offers a cost savings of up to 70% in therapy and will be dispensable only on prescription.

Specialty Adhesive Market Scope:

Report Metric	Details
Anti-Diabetic Drug Market Size in 2025	US$153.176 billion
Anti-Diabetic Drug Market Size in 2030	US$229.19 billion
Growth Rate	CAGR of 9.33%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Diabetes Type Drug Type Route of Administration Sales Channel Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Anti-Diabetic Drug Market	AstraZeneca Pfizer Inc. Merck & Co., Inc. Novo Nordisk A/S Eli Lilly and Company
Customization Scope	Free report customization with purchase

 

The global anti-diabetic drug market is analyzed into the following segments:

• By Diabetes Type
  • Type 1
  • Type 2
• By Drug Type
  • Amylinomimetic drug
  • Biguanides
  • Alpha-glucosidase inhibitors
  • Sodium-glucose transporter (SGLT) 2 inhibitors
  • Others
• By Route of Administration
  • Oral
  • Insulin
• By Sales Channel
  • Prescription
  • Over-The-Counter (OTC)
• By Geography
  • North America
    • USA
    • Canada              
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Taiwan
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-DIABETIC DRUG MARKET BY DIABETES TYPE

5.1. Introduction

5.2. Type 1

5.3. Type 2

6. GLOBAL ANTI-DIABETIC DRUG MARKET BY DRUG TYPE 

6.1. Introduction

6.2. Amylinomimetic drug

6.3. Biguanides

6.4. Alpha-glucosidase inhibitors

6.5. Sodium-glucose transporter (SGLT) 2 inhibitors

6.6. Others

7. GLOBAL ANTI-DIABETIC DRUG MARKET BY ROUTE OF ADMINISTRATION 

7.1. Introduction

7.2. Oral 

7.3. Insulin

8. GLOBAL ANTI-DIABETIC DRUG MARKET BY SALES CHANNEL 

8.1. Introduction

8.2. Prescription

8.3. Over-The-Counter (OTC)

9. GLOBAL ANTI-DIABETIC DRUG MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Diabetes Type

9.2.2. By Drug Type

9.2.3. By Route of Administration

9.2.4. By Sales Channel

9.2.5. By Country

9.2.5.1. USA

9.2.5.2. Canada

9.2.5.3. Mexico

9.3. South America

9.3.1. By Diabetes Type

9.3.2. By Drug Type

9.3.3. By Route of Administration

9.3.4. By Sales Channel

9.3.5. By Country

9.3.5.1. Brazil

9.3.5.2. Argentina

9.3.5.3. Others

9.4. Europe

9.4.1. By Diabetes Type

9.4.2. By Drug Type

9.4.3. By Route of Administration

9.4.4. By Sales Channel

9.4.5. By Country

9.4.5.1. UK

9.4.5.2. Germany

9.4.5.3. France

9.4.5.4. Spain

9.4.5.5. Italy

9.4.5.6. Others

9.5. Middle East and Africa

9.5.1. By Diabetes Type

9.5.2. By Drug Type

9.5.3. By Route of Administration

9.5.4. By Sales Channel

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.2. Israel

9.5.5.3. UAE

9.5.5.4. Others

9.6. Asia Pacific

9.6.1. By Diabetes Type

9.6.2. By Drug Type

9.6.3. By Route of Administration

9.6.4. By Sales Channel

9.6.5. By Country

9.6.5.1. China

9.6.5.2. Japan

9.6.5.3. India

9.6.5.4. South Korea

9.6.5.5. Taiwan

9.6.5.6. Thailand

9.6.5.7. Indonesia

9.6.5.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. AstraZeneca

11.2. Pfizer Inc.

11.3. Merck & Co., Inc.

11.4. Novo Nordisk A/S

11.5. Eli Lilly and Company

11.6. Glenmark Pharmaceuticals Ltd.

11.7. Abbott

11.8. Boehringer Ingelheim International GmbH

AstraZeneca

Pfizer Inc.

Merck & Co., Inc.

Novo Nordisk A/S

Eli Lilly and Company

Glenmark Pharmaceuticals Ltd.

Abbott

Boehringer Ingelheim International GmbH